Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Novartis
 More »

  • VC Firm Partners with Amgen, Novartis to Form 15+ Biotech Startups
    company's VC fund, Amgen Ventures-and Novartis in an effort to fuel translational ... relationships is to provide Amgen and Novartis with strategic proximity to Atlas ...
    5-17-2013
  • Seasoned Drugs Offer Therapeutic Gold Mine
    ... Pollastri. "We use the drugs themselves as a starting point, but we don't repurpose the drugs themselves." Recently they discovered that a drug made by Novartis, currently in ...
    5-15-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, Merck, Mitsubishi Tanabe, Novartis, Pfizer, and Sanofi-in developing the DILIsym(tm) predictive mathematical model of ...
    5-15-2013
  • Making Vaccines from Parts
    Novartis Vaccines and Diagnostics' Philip Dormitzer, Ph.D., and his colleagues today report in Science Translational Medicine that they have successfully started and completed a ...
    5-14-2013
  • FDA OKs Novartis' Drug for Childhood Arthritis
    Ilaris is, according to Novartis, the first interleukin-1 beta (IL-1 beta) inhibitor ... added Timothy Wright, M.D., global head of development at Novartis Pharmaceuticals. ...
    5-10-2013
  • Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral...
    vector-encoding CTL019 technology, which Novartis et al., will use to transduce patients' ... According to Edison Research Investment, Oxford BioMedica's deal with Novartis is expected ...
    5-1-2013
  • GEN | Biolinks
    ... NovaBay Pharmaceuticals, Inc Novabiotics Ltd Novadigm Therapeutics, Inc Novartis Novartis Molecular Diagnostics Novasep Process Novavax, Inc Novici Biotech Novira ...
  • Novartis Cuts 300 Jobs, Names New CFO
    Reporting its first-quarter financial results this week, Novartis announced a ... The pharma giant also named Harry Kirsch its new CFO. Novartis plans to reduce staff at ...
    4-24-2013
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    ... AZ, BMS, Eli Lilly, Gilead, Glaxo, Janssen, Merck, Mitsubishi Tanabe, Novartis , Pfizer, and Sanofi-in developing the DILIsym(tm) predictive mathematical model of ...
    4-22-2013
  • Report: Orphan Drugs Cheaper to Bring to Market, Offer Better...
    According to the report, Novartis led 2012 orphan drug sales, raking in $10.9 billion. ... EvaluatePharma expects Novartis will remain the industry leader through 2018, at which ...
    4-22-2013
  • Pathway Analysis to Decipher Data
    ... It would be interesting to determine which regulators are responsible for a certain gene expression profile in a specific cancer type." Pathway analysis has helped Novartis perform ...
    4-15-2013
  • CEO Perks
    ... value and non-qualified deferred compensation earnings, $2.05 million Joseph Jimenez Novartis, CEO Perks and "other benefits": CHF 128,734 ($138,274), including unspecified ...
    4-12-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    Signifor® (pasireotide) 2012 sales: $3 million 2 Marketer(s): Novartis Indication(s): Cushing's disease in adult patients for whom pituitary surgery is not an option or has not ...
    4-4-2013
  • Scaling Up Peptide Drugs
    The Novartis drug Signifor® (pasireotide) for the treatment of Cushing's disease received approval in the EU in 2012, and FDA approval in the U.S. is expected in 2013. We estimate ...
    4-1-2013
  • Clinigen Buys Cardioxane from Novartis for $33M
    therapy Cardioxane® (dexrazoxane) from Novartis for $33 million cash, reasoning that new ... Theravance. "Acquiring Cardioxane from Novartis is another major step forward for us," ...
    3-26-2013
  • More »

    Journal Articles

  • Is There a Role for Sandostatin Treatment in Patients with Progressive...
    Susanne Kohlfuerst, Isabel Igerc, Hans-Juergen Gallowitsch, Iris Gomez, Ewald Kresnik, Sabine Matschnig, Peter Lind
    Thyroid
    In the case of positive receptor scintigraphy, patients were treated with 20mg Sandostatin LAR® (Novartis Pharmaceuticals, Basel, Switzerland) once per month intramuscularly over ...
  • Effect of Different Dose Schedules of 0.15% Unoprostone Isopropyl...
    Kirk N. Gelatt, Edward O. Mackay, Thomas Dashiell, Alison Biken
    Journal of Ocular Pharmacology and Therapeutics
    The changes in intraocular pressure (IOP) and pupil size (PS) after instillations of 0.15% unoprostone isopropyl (Rescula, Novartis Ophthalmics, Duluth, GA) were investigated in ...
  • Glucagon-Like Peptide-1 as a Treatment Option for Type 2 Diabetes...
    B. Gallwitz
    Diabetes Technology & Therapeutics
    in clinical trials. Dipeptidyl peptidase IV inhibitors (e.g., Vildagliptin® [Novartis, Basel, Switzerland]) that inhibit the enzyme responsible for incretin degradation ...
  • Treatment of Painful Bone Metastases in Hormone-Refractory Prostate...
    Marnix G.E.H. Lam, John M.H. de Klerk, Bernard A. Zonnenberg
    Journal of Palliative Medicine
    ...enediaminetetramethylphosphonic acid (153Sm-EDTMP; Quadramet®, CIS bio International, Saclay, France) in combination with zoledronic acid (Zometa®, Novartis, Stein, Switzerland). ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll